The prognosis of triple-negative breast cancer with metastases after chemotherapy remains dismal. We report the case of a 50-year-old female with first disease recurrence at the axillary lymph node and, later on, bilateral pulmonary metastases with severe shortness of breath. The patient received low-dose immune checkpoint blockade (concurrent nivolumab and ipilimumab) weekly over 3 weeks with regional hyperthermia 3 times a week, followed by systemic fever-range hyperthermia induced by interleukin-2 for 5 days. She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases. This exceptional response should instigate further research efforts with this protocol, which consists only of approved drugs and treatments.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247552PMC
http://dx.doi.org/10.1177/1534735418794867DOI Listing

Publication Analysis

Top Keywords

triple-negative breast
8
breast cancer
8
low-dose immune
8
immune checkpoint
8
checkpoint blockade
8
pulmonary metastases
8
metastases
5
complete clinical
4
clinical remission
4
remission stage
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!